What is KPTI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KPTI?

P/E (TTM) is n/a and 52-week range is $0.60 to $10.99 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KPTI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KPTI?

The company profile lists revenue (TTM) near $115M, net income (TTM) near $-17.60B, EPS (TTM) near $-12.84 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Karyopharm Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Newton, Massachusetts, US, 22.7M shares outstanding, ISIN US48576U2050 when available from company profile and filing metadata.

Karyopharm Therapeutics Inc

$KPTI

Health Care · Biotechnology

IR Run Scenarios

$0.60

+0.83%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. The company is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Employees

228

Website

karyopharm.com/

IPO

2013-11-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)